N-丙基-4-氟苯磺酰胺 | 433-05-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-丙基-4-氟苯磺酰胺
• 中文别名: N-丙基4-氟苯磺酰胺
• 英文名称: 4-fluoro-N-propylbenzenesulfonamide
• 英文别名: 4-fluoro-benzenesulfonic acid propylamide；4-Fluor-benzolsulfonsaeure-propylamid
• CAS: 433-05-6
• 化学式: C₉H₁₂FNO₂S
• mdl: MFCD01212870
• 分子量: 217.264
• InChiKey: MTBBWACEQXVMRS-UHFFFAOYSA-N

物化性质

• 沸点：
  308.2±44.0 °C(Predicted)
• 密度：
  1.225±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2935009090

SDS

N-丙基-4-氟苯磺酰胺MSDS英文版

反应信息

• 作为反应物：
  描述：

  顺-1,2-二氯乙烯 、 N-丙基-4-氟苯磺酰胺 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以92%的产率得到N-ethynyl-4-fluoro-N-propylbenzenesulfonamide
  参考文献：
  名称：

  酰胺的无过渡金属一步合成

  摘要：

  提出了一种强大的无过渡金属的一步法，用于从磺酰胺和（Z）-1,2-二氯烯烃或炔基氯化物合成乙酰胺。该方法不仅对内部的神经酰胺有效，而且对末端的神经酰胺也适用。各种官能团，甚至乙烯基部分都是相容的，因此，该策略提供了进一步官能化的机会。

  DOI：

  10.1021/acs.joc.8b03192
• 作为产物：
  描述：

  正丙胺 、 4-氟苯磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-丙基-4-氟苯磺酰胺
  参考文献：
  名称：

  酰胺的无过渡金属一步合成

  摘要：

  提出了一种强大的无过渡金属的一步法，用于从磺酰胺和（Z）-1,2-二氯烯烃或炔基氯化物合成乙酰胺。该方法不仅对内部的神经酰胺有效，而且对末端的神经酰胺也适用。各种官能团，甚至乙烯基部分都是相容的，因此，该策略提供了进一步官能化的机会。

  DOI：

  10.1021/acs.joc.8b03192

文献信息

• Substituted azetidinones
  申请人：Bannister Thomas

  公开号：US20070105832A1

  公开（公告）日：2007-05-10

  Compounds are provided which have the structure Wherein A, B, C, D, m, Y, Ra, Rc, Rd, and Rd′ are as described herein, and which are useful as inhibitors of tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa, and urokinase-type plasminogen activator and may be employed in preventing and/or treating asthma, chronic asthma, allergic rhinitis, and thrombotic disorders.

  提供了化合物，其结构如下：其中A、B、C、D、m、Y、Ra、Rc、Rd和Rd'如本文所述，并且这些化合物可作为抑制剂用于抑制组胺酶、凝血酶、胰蛋白酶、Xa因子、VIIa因子、XIa因子和尿激酶型纤溶酶原激活剂，并可用于预防和/或治疗哮喘、慢性哮喘、过敏性鼻炎和血栓性疾病。
• SUBSTITUTED AZETIDINONES
  申请人：Bannister Thomas

  公开号：US20100144698A1

  公开（公告）日：2010-06-10

  Compounds are provided which have the structure Wherein A, B, C, D, m, Y, Ra, Rc, Rd, and Rd′ are as described herein, and which are useful as inhibitors of tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa, and urokinase-type plasminogen activator and may be employed in preventing and/or treating asthma, chronic asthma, allergic rhinitis, and thrombotic disorders.

  提供了具有以下结构的化合物： 其中A，B，C，D，m，Y，Ra，Rc，Rd和Rd'如本文所述，并且可用作抑制剂尝试酶，凝血酶，胰蛋白酶，因子Xa，因子VIIa，因子XIa和尿激酶型纤溶酶原激活剂，并可用于预防和/或治疗哮喘，慢性哮喘，过敏性鼻炎和血栓性疾病。
• Visible‐Light‐Induced Diradical‐Mediated <i>ipso</i> ‐Cyclization towards Double Dearomative [2+2]‐Cycloaddition or Smiles‐Type Rearrangement
  作者：Guangjin Zhen、Guohui Zeng、Kai Jiang、Furong Wang、Xiaohui Cao、Biaolin Yin

  DOI：10.1002/chem.202203217

  日期：2023.3.13

  ipso-cyclization involving dearomatizing spiro-intermediates of aromatic compounds towards divergent reaction pathways deserves investigation but has been rarely reported so far. By tuning the rate of C−S bond cleavage in the key dearomatizing spiro intermediate, a chemical divergent reaction of (hetero)aryl sulfonamides has been achieved in a visible-light-induced energy transfer reaction pathway involving diradical

  双自由基介导的 ipso环化涉及将芳香族化合物的螺环中间体脱芳构化到不同的反应途径值得研究，但迄今为止很少有报道。通过调节关键的脱芳构化螺环中间体中 C-S 键的断裂速率，在涉及双自由基物种的可见光诱导能量转移反应途径中实现了（杂）芳基磺酰胺的化学发散反应。
• Inhibitors
  申请人：VIVORYON THERAPEUTICS N.V.

  公开号：US11339152B2

  公开（公告）日：2022-05-24

  The invention relates to a compound of formula (I): A-B-D-E (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein: A is selected from monocyclic and bicyclic heteroaryl, which may independently substituted by alkyl or amino; B is selected from alkyl, heteroalkyl, alkyl-amino, aryl, heteroaryl, cycloalkyl, heterocyclyl and alkylene, wherein said groups may independently be substituted by alkyl; D is selected from aryl-amino, heteroaryl-amino, cycloalkyl-amino, heterocyclyl, heterocyclyl-amino, urea, thioamide, thiourea, sulfonamide, sulfoximine and sulfamoyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups may independently be substituted; and E is selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups may independently be substituted. The compounds of formula (I) are inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

  本发明涉及一种式(I)化合物：A-B-D-E (I)或其药学上可接受的盐、溶液或多晶型物，包括其所有同分异构体和立体异构体，其中：A 选自单环和双环杂芳基，它们可独立地被烷基或氨基取代；B 选自烷基、杂烷基、烷基氨基、芳基、杂芳基、环烷基、杂环烷基和亚烷基，其中所述基团可独立地被烷基取代；D 选自芳基-氨基、杂芳基-氨基、环烷基-氨基、杂环基、杂环基-氨基、脲、硫酰胺、硫脲、磺酰胺、亚磺酰亚胺和氨基磺酰基，其中所述芳基、杂芳基、环烷基和杂环基可独立地被取代；E 选自芳基、杂芳基、环烷基和杂环烷基，其中所述芳基、杂芳基、环烷基和杂环烷基可独立地被取代。式（I）化合物是谷氨酰胺酰环化酶（QC，EC 2.3.2.5）的抑制剂。QC 催化 N 端谷氨酰胺残基在氨释放下分子内环化为焦谷氨酸（5-氧代-脯氨酰，pGlu*），并催化 N 端谷氨酸残基在水释放下分子内环化为焦谷氨酸。
• Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods
  作者：Dhruba Sarkar、Edward T. Olejniczak、Jason Phan、Jesse A. Coker、Jiqing Sai、Allison Arnold、Yugandhar Beesetty、Alex G. Waterson、Stephen W. Fesik

  DOI：10.1021/acs.jmedchem.0c00511

  日期：2020.8.13

  The nucleotide exchange factor Son of Sevenless (SOS) catalyzes the activation of RAS by converting it from its inactive GDP-bound state to its active GTP-bound state. Recently, we have reported the discovery of small-molecule allosteric activators of SOS1 that can increase the amount of RAS-GTP in cells. The compounds can inhibit ERIC phosphorylation at higher concentrations by engaging a feedback mechanism. To further study this process, we sought different chemical matter from an NMR-based fragment screen using selective methyl labeling. To aid this process, several Ile methyl groups located in different binding sites of the protein were assigned and used to categorize the NMR hits into different classes. Hit to lead optimization using an iterative structure-based design paradigm resulted in compounds with improvements in binding affinity. These improved molecules of a different chemical class increase SOS1'-mediated nucleotide exchange on RAS and display cellular action consistent with our prior results.